Committee Composition

Patrick Sullivan

Mr. Sullivan has served as Insulet's Chief Executive Officer and Chairman of the Board since October 2016. Previously, he served as President, Chief Executive Officer and Director since September 2014. Prior to joining Insulet, Mr. Sullivan spent five years at Constitution Medical Investors as the Chairman and CEO. Mr. Sullivan served as Executive Chairman of Hologic from its merger with Cytyc Corporation in October 2007 until May 2008, having previously served Cytyc as Chairman, President and Chief Executive Officer. Previously, Mr. Sullivan was employed in marketing roles of increasing responsibility at Abbott Laboratories, a diversified healthcare company, and as a consultant with McKinsey & Company, an international consulting firm. Mr. Sullivan serves as a director of PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment. Mr. Sullivan holds a Bachelor of Science degree, with Distinction, from the United States Naval Academy and an M.B.A., with Distinction, from Harvard Business School.

Sally W. Crawford

Ms. Crawford has served on our Board of Directors since 2008 and served as our Lead Director from 2009 through May 2013. She also serves on the Board of Directors of Hologic, Inc., Universal American and Prolacta Bioscience. She is a healthcare consultant and the former Chief Operating Officer of Healthsource Inc., a publicly held managed care organization, headquartered in New Hampshire. During her tenure at Healthsource, she led development of the company's operating systems and marketing strategies and supported strategic alliances with physicians, hospitals, insurers and other healthcare companies. Since January 1997, Ms. Crawford has been a Healthcare Consultant in New Hampshire for clients such as Bayer Healthcare Diabetes Division, as well as healthcare investors, providers, regulators and managed care payers. Ms. Crawford earned a Bachelor of Arts in English from Smith College and an Master of Science in Communication from Boston University.

Recent Stock Transactions by Sally W. Crawford
Date Type Shares Traded Price Range
May 11, 2016 Acquisition (Non Open Market) 3,810 n/a
May 13, 2015 Acquisition (Non Open Market) 4,039 n/a
Jun 2, 2014 Acquisition (Non Open Market) 4,000 n/a
Jan 17, 2014 Option Execute 3,000 14.48 - 20.90
Aug 29, 2013 Sell 9,000 33.42
Jun 14, 2013 Automatic Sell 31,000 30.47
Jun 14, 2013 Option Execute 31,000 5.50 - 14.48
Jun 3, 2013 Acquisition (Non Open Market) 4,000 n/a
Jun 1, 2012 Acquisition (Non Open Market) 4,000 n/a
May 12, 2011 Acquisition (Non Open Market) 4,000 n/a
Jun 1, 2010 Acquisition (Non Open Market) 4,000 n/a
John Fallon MD

Dr. Fallon has served on our Board of Directors since October 2012. He also serves on the Board of Directors of AMAG Pharmaceuticals, Exact Sciences Corporation and Collegium Pharmaceutical, Inc. From 2004 through 2015, Dr. Fallon served as the Chief Physician Executive and Senior Vice President of Blue Cross Blue Shield of Massachusetts. From 2000 to 2004, he held the position of Chief Executive Officer for Clinical Affairs at the State University of New York Medical Center.  In 1995, Dr. Fallon became a founding Trustee of Partners Community HealthCare Inc. (“PCHI”), the Physician Network for Partners HealthCare System founded by The Massachusetts General Hospital and The Brigham and Women’s Hospital, and in 1998 he went on to become Chairman of PCHI.  Dr. Fallon has also served as Founder, President and Chief Executive Officer of North Shore Health System, Chief Medical Executive and later Chief Executive Officer of Charter Professional Services Corporation, and First Chief Medical Officer for North Shore Medical Center. Dr. Fallon was a practicing internal medicine physician for more than 25 years and has served on multiple healthcare boards and committees, including Temple University School of Medicine Board of Advisors, Editorial Board of American Journal of Medical Quality, and the Alliance for Health Care Improvement Board.  He holds a Bachelor of Arts in Chemistry from College of the Holy Cross, a Doctor of Medicine from Tufts University School of Medicine, and a Master of Business Administration from University of South Florida. Dr. Fallon brings over 35 years of experience as a practicing physician, senior executive and participation in numerous medical boards and committees in the health care industry.

Jessica Hopfield, PhD

Dr. Jessica Hopfield has served on our Board of Directors since July 2015 and as our Lead Director since August 2016. In October 2015, Dr. Hopfield was appointed, and currently serves, as Chairperson of the Board of Trustees of the Joslin Diabetes Center and she serves as an independent director of rEVO Biologics, Inc. From 2013 to October 2015, Dr. Hopfield served as the Vice Chair of the Board of Trustees of the Joslin Diabetes Center. Dr. Hopfield is a distinguished healthcare executive and diabetes expert with over two decades of experience in the medical and healthcare fields. She is a strategic advisor and investor in start-up healthcare firms seeking to commercialize innovative intellectual property. She was a partner of McKinsey & Company in their Global Pharmaceuticals and Medical Devices Practice and while at McKinsey from 1995 to 2009, she served clients across pharmaceutical, biotech, medical device and consumer industries with a focus on strategy, R&D management and marketing. Dr. Hopfield also previously held management positions at Merck Sharp & Dohme in Clinical Development, Outcomes Research, and Marketing. Dr. Hopfield earned a Masters of Business Administration from Harvard Graduate School of Business Administration as a Baker Scholar, a PhD in Neuroscience/Biochemistry from The Rockefeller University, and a Bachelor of Science from Yale College.

David A. Lemoine

Mr. Lemoine has served on our Board of Directors since February 2016. He also serves as Chair of the Audit Committee and on the Corporate Governance and Nominating Committee of the Board of Directors of The L.S. Starrett Company. Mr. Lemoine has over 40 years of audit and finance experience and a deep knowledge of accounting, financial reporting and internal controls. From 1985 until his retirement in 2010, he held the position of Audit Partner at Deloitte & Touche LLP. He served as Deloitte’s Boston office Audit Partner-in-Charge from 1995 to 2000. From 1980 to 1985, he was Senior Vice President, Finance and Administration at Briox Technologies, Inc., a medical equipment manufacturer of electronics home healthcare. In addition to his board and committee experience, Mr. Lemoine brings more than 40 years of experience in accounting across a broad array of industries, including manufacturing, biotechnology, pharmaceutical, technology and healthcare. Mr. Lemoine was an adjunct professor at Boston College’s Carroll School of Management from 2008 to 2014, where he taught courses in Ethics and Accounting. Mr. Lemoine earned a Masters in Accounting from Northeastern University and a B.A. in Economics from Boston College. He is a Certified Public Accountant and a member of the Massachusetts Society of CPAs.

Timothy J. Scannell

Mr. Scannell has served on our Board of Directors since August 2014. He is currently Group President of MedSurg & Neurotechnology at Stryker Corporation, a global leader in the medical technology industry. Mr. Scannell oversees six of Stryker’s operating divisions in his role including Instruments, Medical, Endoscopy, Neurovascular, CMF, and Sustainability Solutions. Mr. Scannell began his career with Stryker at the Endoscopy Division in 1990 where he served in a range of sales and marketing leadership roles and progressed to the position of Executive Vice President. In 2001, he was appointed Vice President and General Manager of Stryker's Biotech Division. In 2003 he was promoted to Vice President and General Manager of Stryker's Spine Division and later to President of Spine. He became the Group President of Spine & Endoscopy in 2008 and was named Group President, MedSurg & Spine in August of 2009. Mr. Scannell holds Bachelor’s and Master’s degrees in Business Administration from the University of Notre Dame.

Regina Sommer

Ms. Sommer has served on our Board of Directors since 2008 and also currently serves on the Board of Directors of WEX INC. Previously, Ms. Sommer served on the Board of Directors of ING Direct from 2008 to 2012 and also Soundbite Communications from 2006 to 2012. From 2002 through 2005, she served as the Vice President and Chief Financial Officer of Netegrity, Inc., which was acquired by Computer Associates in November 2004. From 1999 to 2001, she served as the Vice President and Chief Financial Officer of Revenio, Inc. From 1995 to 1999, she served as Senior Vice President and Chief Financial Officer of Open Market, Inc., and from 1989 to 1994, she served as the Vice President of Finance at The Olsten Corporation. She also worked at PricewaterhouseCoopers LLP from 1980 to 1989. Ms. Sommer earned a Bachelor of Arts degree from the College of the Holy Cross. She was formerly licensed in Massachusetts as a Certified Public Accountant.

Recent Stock Transactions by Regina Sommer
Date Type Shares Traded Price Range
Mar 13, 2017 Sell 40,000 45.00
Mar 13, 2017 Option Execute 40,000 7.06 - 20.90
May 25, 2016 Sell 8,019 30.42
May 11, 2016 Acquisition (Non Open Market) 3,810 n/a
May 13, 2015 Acquisition (Non Open Market) 4,039 n/a
Jun 2, 2014 Acquisition (Non Open Market) 4,000 n/a
Aug 15, 2013 Sell 5,000 33.32
Jun 3, 2013 Acquisition (Non Open Market) 4,000 n/a
Jun 1, 2012 Acquisition (Non Open Market) 4,000 n/a
May 12, 2011 Acquisition (Non Open Market) 4,000 n/a
Jun 1, 2010 Acquisition (Non Open Market) 4,000 n/a
Joseph Zakrzewski

Mr. Zakrzewski has served on our Board of Directors since 2008. He currently serves as Chairman of the Board of Directors of Onxeo S.A., a public company specializing in the development of orphan oncology drugs. He serves on the board of directors of Acceleron Pharma, Inc., a clinical stage biopharmaceutical company, and Amarin Corporation, a biopharmaceutical company. Mr. Zakrzewski served as Amarin Corporation’s Executive Chairman of the Board of Directors from January 2010 to December 2013, and as its chief executive officer from November 2010 to December 2013. He also serves on the boards of directors of several privately held corporations. From 2010 to 2011, Mr. Zakrzewski served as a venture partner with Orbimed Advisors LLC, the world’s largest healthcare- dedicated investment firm. From 2007 to 2010, he served as Chairman of the Board of Directors, President and Chief Executive Officer of Xcellerex Inc., a privately-held company focusing on commercializing its proprietary, next-generation manufacturing technology for biotherapeutics and vaccines. From 2005 to 2007, he served as the Chief Operating Officer of Reliant Pharmaceuticals, Inc. and from 1988 to 2005, he served in a variety of positions at Eli Lilly and Company, including as Vice President, Corporate Business Development, from 2003 to 2005. From 2014 to 2015, Mr. Zakrzewski served on the board of directors of LipoScience, Inc., a diagnostics company focused in the areas of lipoproteins and small molecule metabolites. He earned a Bachelor of Science in Chemical Engineering, a Master of Science in Biochemical Engineering from Drexel University, and a Master of Business Administration from Indiana University. Mr. Zakrzewski brings extensive boardroom experience, operational experience as a chief executive officer and prior experience in the pharmaceutical industry.

Recent Stock Transactions by Joseph Zakrzewski
Date Type Shares Traded Price Range
Mar 2, 2017 Sell 40,000 46.31 - 48.03
Mar 2, 2017 Option Execute 40,000 7.06 - 20.90
May 11, 2016 Acquisition (Non Open Market) 3,810 n/a
May 13, 2015 Acquisition (Non Open Market) 4,039 n/a
Jun 2, 2014 Acquisition (Non Open Market) 4,000 n/a
Jun 3, 2013 Acquisition (Non Open Market) 4,000 n/a
Jun 1, 2012 Acquisition (Non Open Market) 4,000 n/a
Feb 17, 2012 Sell 3,000 20.20
Feb 16, 2012 Sell 2,000 20.67
May 12, 2011 Acquisition (Non Open Market) 4,000 n/a
Jun 1, 2010 Acquisition (Non Open Market) 4,000 n/a

Stock transaction information provided by EDGAR Online. Insulet Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

Board of Directors Audit Nominating, Governance and Risk Compensation
Image of Sally W. Crawford
Sally W. Crawford
Director, Hologic, Universal American, Prolacta Bioscience and Healthcare Consultant

Ms. Crawford has served on our Board of Directors since 2008 and served as our Lead Director from 2009 through May 2013. She also serves on the Board of Directors of Hologic, Inc., Universal American and Prolacta Bioscience. She is a healthcare consultant and the former Chief Operating Officer of Healthsource Inc., a publicly held managed care organization, headquartered in New Hampshire. During her tenure at Healthsource, she led development of the company's operating systems and marketing strategies and supported strategic alliances with physicians, hospitals, insurers and other healthcare companies. Since January 1997, Ms. Crawford has been a Healthcare Consultant in New Hampshire for clients such as Bayer Healthcare Diabetes Division, as well as healthcare investors, providers, regulators and managed care payers. Ms. Crawford earned a Bachelor of Arts in English from Smith College and an Master of Science in Communication from Boston University.

 
Image of John Fallon MD
John Fallon MD
Director, AMAG Pharmaceuticals, Exact Sciences Corporation and Collegium Pharmaceutical, Inc.

Dr. Fallon has served on our Board of Directors since October 2012. He also serves on the Board of Directors of AMAG Pharmaceuticals, Exact Sciences Corporation and Collegium Pharmaceutical, Inc. From 2004 through 2015, Dr. Fallon served as the Chief Physician Executive and Senior Vice President of Blue Cross Blue Shield of Massachusetts. From 2000 to 2004, he held the position of Chief Executive Officer for Clinical Affairs at the State University of New York Medical Center.  In 1995, Dr. Fallon became a founding Trustee of Partners Community HealthCare Inc. (“PCHI”), the Physician Network for Partners HealthCare System founded by The Massachusetts General Hospital and The Brigham and Women’s Hospital, and in 1998 he went on to become Chairman of PCHI.  Dr. Fallon has also served as Founder, President and Chief Executive Officer of North Shore Health System, Chief Medical Executive and later Chief Executive Officer of Charter Professional Services Corporation, and First Chief Medical Officer for North Shore Medical Center. Dr. Fallon was a practicing internal medicine physician for more than 25 years and has served on multiple healthcare boards and committees, including Temple University School of Medicine Board of Advisors, Editorial Board of American Journal of Medical Quality, and the Alliance for Health Care Improvement Board.  He holds a Bachelor of Arts in Chemistry from College of the Holy Cross, a Doctor of Medicine from Tufts University School of Medicine, and a Master of Business Administration from University of South Florida. Dr. Fallon brings over 35 years of experience as a practicing physician, senior executive and participation in numerous medical boards and committees in the health care industry.

   
Image of Jessica Hopfield, PhD
Jessica Hopfield, PhD
Healthcare Strategic Advisor and Director, Joslin Diabetes Center and rEVO Biologics

Dr. Jessica Hopfield has served on our Board of Directors since July 2015 and as our Lead Director since August 2016. In October 2015, Dr. Hopfield was appointed, and currently serves, as Chairperson of the Board of Trustees of the Joslin Diabetes Center and she serves as an independent director of rEVO Biologics, Inc. From 2013 to October 2015, Dr. Hopfield served as the Vice Chair of the Board of Trustees of the Joslin Diabetes Center. Dr. Hopfield is a distinguished healthcare executive and diabetes expert with over two decades of experience in the medical and healthcare fields. She is a strategic advisor and investor in start-up healthcare firms seeking to commercialize innovative intellectual property. She was a partner of McKinsey & Company in their Global Pharmaceuticals and Medical Devices Practice and while at McKinsey from 1995 to 2009, she served clients across pharmaceutical, biotech, medical device and consumer industries with a focus on strategy, R&D management and marketing. Dr. Hopfield also previously held management positions at Merck Sharp & Dohme in Clinical Development, Outcomes Research, and Marketing. Dr. Hopfield earned a Masters of Business Administration from Harvard Graduate School of Business Administration as a Baker Scholar, a PhD in Neuroscience/Biochemistry from The Rockefeller University, and a Bachelor of Science from Yale College.

   
Image of David A. Lemoine
David A. Lemoine
Director, The L.S. Starrett Company

Mr. Lemoine has served on our Board of Directors since February 2016. He also serves as Chair of the Audit Committee and on the Corporate Governance and Nominating Committee of the Board of Directors of The L.S. Starrett Company. Mr. Lemoine has over 40 years of audit and finance experience and a deep knowledge of accounting, financial reporting and internal controls. From 1985 until his retirement in 2010, he held the position of Audit Partner at Deloitte & Touche LLP. He served as Deloitte’s Boston office Audit Partner-in-Charge from 1995 to 2000. From 1980 to 1985, he was Senior Vice President, Finance and Administration at Briox Technologies, Inc., a medical equipment manufacturer of electronics home healthcare. In addition to his board and committee experience, Mr. Lemoine brings more than 40 years of experience in accounting across a broad array of industries, including manufacturing, biotechnology, pharmaceutical, technology and healthcare. Mr. Lemoine was an adjunct professor at Boston College’s Carroll School of Management from 2008 to 2014, where he taught courses in Ethics and Accounting. Mr. Lemoine earned a Masters in Accounting from Northeastern University and a B.A. in Economics from Boston College. He is a Certified Public Accountant and a member of the Massachusetts Society of CPAs.

   
Image of Timothy J. Scannell
Timothy J. Scannell
Group President, MedSurg & Neurotechnology, Stryker Corporation

Mr. Scannell has served on our Board of Directors since August 2014. He is currently Group President of MedSurg & Neurotechnology at Stryker Corporation, a global leader in the medical technology industry. Mr. Scannell oversees six of Stryker’s operating divisions in his role including Instruments, Medical, Endoscopy, Neurovascular, CMF, and Sustainability Solutions. Mr. Scannell began his career with Stryker at the Endoscopy Division in 1990 where he served in a range of sales and marketing leadership roles and progressed to the position of Executive Vice President. In 2001, he was appointed Vice President and General Manager of Stryker's Biotech Division. In 2003 he was promoted to Vice President and General Manager of Stryker's Spine Division and later to President of Spine. He became the Group President of Spine & Endoscopy in 2008 and was named Group President, MedSurg & Spine in August of 2009. Mr. Scannell holds Bachelor’s and Master’s degrees in Business Administration from the University of Notre Dame.

   
Image of Regina Sommer
Regina Sommer
Director, WEX

Ms. Sommer has served on our Board of Directors since 2008 and also currently serves on the Board of Directors of WEX INC. Previously, Ms. Sommer served on the Board of Directors of ING Direct from 2008 to 2012 and also Soundbite Communications from 2006 to 2012. From 2002 through 2005, she served as the Vice President and Chief Financial Officer of Netegrity, Inc., which was acquired by Computer Associates in November 2004. From 1999 to 2001, she served as the Vice President and Chief Financial Officer of Revenio, Inc. From 1995 to 1999, she served as Senior Vice President and Chief Financial Officer of Open Market, Inc., and from 1989 to 1994, she served as the Vice President of Finance at The Olsten Corporation. She also worked at PricewaterhouseCoopers LLP from 1980 to 1989. Ms. Sommer earned a Bachelor of Arts degree from the College of the Holy Cross. She was formerly licensed in Massachusetts as a Certified Public Accountant.

 
Image of Joseph Zakrzewski
Joseph Zakrzewski
Director, Acceleron Pharmaceuticals, Amarin Pharmaceuticals and Onxeo S.A.

Mr. Zakrzewski has served on our Board of Directors since 2008. He currently serves as Chairman of the Board of Directors of Onxeo S.A., a public company specializing in the development of orphan oncology drugs. He serves on the board of directors of Acceleron Pharma, Inc., a clinical stage biopharmaceutical company, and Amarin Corporation, a biopharmaceutical company. Mr. Zakrzewski served as Amarin Corporation’s Executive Chairman of the Board of Directors from January 2010 to December 2013, and as its chief executive officer from November 2010 to December 2013. He also serves on the boards of directors of several privately held corporations. From 2010 to 2011, Mr. Zakrzewski served as a venture partner with Orbimed Advisors LLC, the world’s largest healthcare- dedicated investment firm. From 2007 to 2010, he served as Chairman of the Board of Directors, President and Chief Executive Officer of Xcellerex Inc., a privately-held company focusing on commercializing its proprietary, next-generation manufacturing technology for biotherapeutics and vaccines. From 2005 to 2007, he served as the Chief Operating Officer of Reliant Pharmaceuticals, Inc. and from 1988 to 2005, he served in a variety of positions at Eli Lilly and Company, including as Vice President, Corporate Business Development, from 2003 to 2005. From 2014 to 2015, Mr. Zakrzewski served on the board of directors of LipoScience, Inc., a diagnostics company focused in the areas of lipoproteins and small molecule metabolites. He earned a Bachelor of Science in Chemical Engineering, a Master of Science in Biochemical Engineering from Drexel University, and a Master of Business Administration from Indiana University. Mr. Zakrzewski brings extensive boardroom experience, operational experience as a chief executive officer and prior experience in the pharmaceutical industry.

 
= Chair
= Member
= Independent Director

Stock transaction information provided by EDGAR Online. Insulet Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.